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Background: The aim of this study was to assess the efficacy, tolerability and safety of risedronate in adults with CF.
Methods: Patients with a lumbar spine (LS), total hip (TH) or femoral neck (FN) bone mineral density (BMD) Z-score of −1 or less were
randomised to receive risedronate 35 mg weekly or placebo, and calcium (1 g)+vitamin D3 (800 IU).
Results: At baseline, BMD Z-scores in the risedronate (n=17) and placebo (n=19) groups were similar. By 24 months, 7/17 risedronate patients
vs 0/19 placebo patients stopped the study medication due to bone pain. After 24 months treatment, the mean difference (95% CI) in change in LS,
TH and FN BMD between the risedronate vs placebo groups was 4.3% (0.4, 8.2) p=0.03; 4.0% (−0.5, 8.6) p=0.08; and 2.4% (-3.5, 8.2) p=0.41.
Conclusions: After two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Bone mineral density; Cystic fibrosis; Fractures; Osteoporosis1. Introduction
Low bone mineral density (BMD) is common in adults with
cystic fibrosis (CF) [1] and results from suboptimal bone mass
accrual in childhood [2] and premature bone loss in early adult
life [3]. Although the Cystic Fibrosis Transmembrane Regulator
(CFTR) is expressed in osteoblasts and osteoclasts [4], it is not⁎ Corresponding author. Tel.: +44 1480 364122; fax: +44 1480 364330.
E-mail address: charles.haworth@papworth.nhs.uk (C.S. Haworth).
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doi:10.1016/j.jcf.2011.07.007known if it affects bone cell activity. However, recent data
suggest that CFTR dysfunction may lead to reduced expression
of osteoprotegerin, the soluble decoy receptor for RANKL and
this may result in increased osteoclastic bone resorption [5].
Chronic pulmonary infection is also thought to stimulate bone
resorption through the effects of pro-inflammatory cytokines on
osteoclast maturation and activity [6–8].
Bisphosphonates are potent inhibitors of osteoclastic bone
resorption and are effective in the prevention of fragility fractures
in postmenopausal women, male osteoporosis and glucocorticoidd by Elsevier B.V. All rights reserved.
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that three monthly bisphosphonate infusions (pamidronate and
zoledronic acid) and oral alendronate (taken daily and weekly) are
effective in increasing BMD in adults with CF [12–15]. However,
bisphosphonate infusions can cause bone pain, particularly after
the first dose [13,16]. To date there have been no studies of the oral
bisphosphonate risedronate in adults with CF. Risedronate is an
aminobisphosphonate which is approved for the prevention and
treatment of osteoporosis in men and postmenopausal women and
glucocorticoid induced osteoporosis [9,10,17,18]. It is believed to
have a shorter half life in bone than alendronate, which is relevant
to females who wish to become pregnant following cessation of
bisphosphonate therapy. The aim of this study was to assess the
long term efficacy, tolerability and safety of risedronate
administered once weekly in adults with CF.
2. Methods
2.1. Participants
Adults with CF aged 18 years and over were recruited
between November 2005 and June 2007 from four UK adult CF
centres: Papworth Hospital, Cambridge; The Royal Brompton
Hospital, London; St James's University Hospital, Leeds; and
Belfast City Hospital, Belfast. The diagnosis of CF was made
on the basis of a positive sweat test or gene analysis and a
consistent CF phenotype.
Eligibility was assessed at a screening visit. Patients were
included if their lumbar spine (LS) or total hip (TH) or femoral
neck (FN) BMD Z-score was −1.0 or less. Exclusion criteria
were the prescription of daily oral glucocorticoids for six weeks
or more in the 12 months preceding the study; breast feeding,
pregnancy, desire to become pregnant within three years; listed
for, or recipient of solid organ transplant; history of gastroscopy
proven oesophageal abnormalities; renal impairment (elevated
serum creatinine and an estimated creatinine clearance of 30 ml/
min or less); hypocalcaemia; previous prescription of bone
active drugs (bisphosphonates, hormone replacement therapy,
raloxifene, calcitriol, calcitonin, teriparatide); biochemical
evidence of vitamin D deficiency in the 12 months prior to
the screening visit (25-hydroxyvitamin D levelb10 ng/ml and
PTH N45 pg/ml); previous poor clinic attendance; previous
poor adherence; pre-terminal illness or other serious concom-
itant illness. The study was approved by the local ethics
committee (Cambridge, UK) and submitted to www.
clinicaltrials.gov.
2.2. Study protocol
Patients were randomised to receive once weekly risedronate
35 mg or identical placebo (Procter & Gamble, Norwich, USA).
Both groups were prescribed Calcichew D3 Forte two tablets
daily (Shire Pharmaceuticals, Hampshire, UK) which provides
1000 mg calcium+800 IU vitamin D3/day. Patients were
advised to continue their standard multivitamin supplements.
Female participants of reproductive age were advised not to
become pregnant for at least 12 months after study completion.Participants commenced the study medication within six
weeks of the screening visit. Study visits were conducted after
3, 6, 12, 18 and 24 months of treatment and included a clinical
assessment and a pregnancy test (in females). X-ray confirmed
fractures, concomitant medications and adverse events were
also recorded.
The serum concentration of C-terminal cross-linked telopep-
tide of collagen type 1 (CTX), a biochemical marker of bone
resorption, was measured at the baseline and six month visits in
24 patients (12 risedronate, 12 placebo). CTX was measured
using the serum CrossLaps ELISA kit (IDS Ltd, UK), which has
an intra-assay variation of 1.8–3.0%.
Adherence was measured through performing a residual
tablet count at each study visit.
2.3. Bone densitometry
The primary outcome measure was change in BMD (LS)
measurements at 24 months of treatment, adjusted for baseline
measurement, using dual energy X-ray absorptiometry (DXA).
Secondary outcome variables included change in BMD (TH and
FN) at 24 months, change in BMD at 12 months and new
vertebral fractures during the 24 months of treatment.
DXA scans were performed on the Hologic Discovery
(Hologic Inc, Bedford, MA) at Belfast City Hospital and
Papworth Hospital, on the GE Lunar DPX-IQ (GE Healthcare,
WI) at the Royal Brompton Hospital and the GE Lunar Prodigy
(GE Healthcare, WI) at St James Hospital. The European spine
phantom (ESP) was scanned at each centre at the start and end
of the study and these data were used to standardise measure-
ments between the different densitometers [19]. BMD was
reported as g/cm2 and as Z-scores. Z-scores were calculated
using Hologic reference data for the lumbar spine and National
Health and Nutrition Examination Survey (NHANES) reference
data for the proximal femur [20]. To monitor quality assurance,
a manufacturer specific spine phantom was scanned at each site
three or more times each week during the study period [21].
There were no significant drifts or jumps in quality assurance
data from each centre and the precision (CV%) of the spine
phantom measurements was 0.35% at Belfast City Hospital,
0.40% at St James Hospital, 0.42% at Papworth Hospital and
0.69% at The Royal Brompton Hospital.
2.4. Fracture determination
Lateral thoracic and lumbar spine X-rays were performed at
the baseline visit and after 24 months of treatment. A blinded
radiologist (PB) assessed all X-rays for vertebral fractures using
the semi quantitative method of Genant et al. [22].
2.5. Statistical analysis
The sample size was based on the rate of change in BMD
observed in a previous CF oral bisphosphonate study [14]. The
assumed mean change (SD) in LS BMD was 5% (3%) in the
risedronate arm and −2% (4%) in the placebo arm. Assuming
two-sided significance of 5% and 90% power, we aimed to
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two year trial. Patients were allocated to risedronate or placebo
using a computer programme to minimise differences between
groups in treatment centre, sex and baseline LS BMD. Only the
study pharmacist had access to the treatment allocation.
Study data were analysed using STATA version 11.0. Data
were summarised as the mean (SD), median (interquartile
range), or number (%). In exploratory analysis differences
between groups were assessed using Fisher's exact test, Mann–
Whitney U test and the Student t-test. For inference mean
differences with 95% confidence intervals are presented. The
differences in BMD measurements were estimated using
general linear models, including baseline values and treatment
group as covariates. Adverse events were tabulated for each
treatment group and incidence rates were compared using log-
linear regression.
The statistical design and analysis followed CONSORT
guidelines [23]. An intention to treat principle was used to
compare the treatment groups. Only patients who completed
24 months of follow up were included in the initial analysis of
primary outcome (n=24). Multiple imputation analyses were
undertaken to estimate primary outcomes for all patients, whilst
incorporating the full variation in measurement. Imputed valuesRandomisati
6 Months 
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18 Months
             24 Months
Screened n=4
Randomised n
Risedronate n=17
Received Risedronate n=17 
Followed up n=15
On Risedronate n=12 
Discontinued Risedronate n=3 
(Withdrew n=2) 
Followed up n=14
On Risedronate n=11 
Discontinued Risedronate n=3 
(Withdrew n=3) 
Followed up n=12
On Risedronate n=9 
Discontinued Risedronate n=3 
(Withdrew n=4, died n=1) 
Followed up n=12
On Risedronate n=9 
Discontinued Risedronate n=3 
(Withdrew n=4, died n=1) 
Fig. 1. CONSORT flow diagram. (NB one placebo patientwere based on baseline BMD, treatment group, spirometry and
treatment centre. Since these analyses gave very similar results
only the completers analysis is included.3. Results
The preliminary results of this study were presented at the
European and North American Cystic Fibrosis conferences in
2010 [24,25].
The CONSORT diagram is shown in Fig. 1. Forty-six
patients were screened for the study. Of these, 8 patients were
excluded due to very low BMD (n=1), BMD Z-score in the LS
and proximal femurN−1 (n=4) and biochemical evidence of
vitamin D deficiency (n=3). A further two patients decided not
to take part in the trial. The remaining 36 patients were recruited
and randomised to risedronate (n=17) or placebo (n=19).
Recruitment became increasingly difficult as the trial pro-
gressed due to the adverse events (bone pain) reported by some
of the initial participants (see below).
Immediately after randomisation one patient in the placebo
group withdrew consent before taking the study medication.
Therefore, only 18 patients were commenced on placebo. Byon
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=36
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Exclusion criteria n=8 
Patient refused n=2 
Placebo n=19
Received Placebo n=18 
Withdrew before taking drug n=1 
Followed up n=17
On placebo n=17 
(Withdrew n=2) 
Followed up n=16
On placebo n=16 
(Withdrew n=2, died n=1) 
Followed up n=15
On placebo n=15 
(Withdrew n=2, died n=2) 
Followed up n=12
On placebo   n=12 
(Withdrew n=3, died n=4) 
at 12 months had incomplete follow up due to illness).
Table 2
Mean (SD) baseline bone mineral density (BMD) and bone biochemistry of
patients in the risedronate and placebo groups.
Risedronate n=17 Placebo n=19 p
Lumbar spine BMD (g/cm2) 0.927 (0.058) 0.909 (0.080) 0.46
Lumbar spine BMD Z-score −1.57 (0.44) −1.82 (0.70) 0.22
Total hip BMD (g/cm2) 0.845 (0.116) 0.879 (0.102) 0.36
Total hip BMD Z-score −1.24 (0.68) −1.06 (0.64) 0.43
Femoral neck BMD (g/cm2) 0.781 (0.096) 0.815 (0.137) 0.41
Femoral neck Z-score −0.95 (0.63) −0.79 (0.89) 0.56
Corrected calcium (mmol/L)
(normal range 2.1–2.50)
2.32 (0.19) 2.36 (0.11) 0.46
Phosphate (mmol/L)
(normal range 0.8–1.4)
1.28 (0.19) 1.15 (0.20) 0.07
Alkaline phosphatase (U/L)
(normal range 30–135)
120.8 (91.9) 106.4 (56.0) 0.57
25-hydroxyvitamin D (ng/ml) 16.1 (7.2) 15.7 (9.9) 0.90
Parathyroid hormone (ng/L)
(normal range 14–72)
32.2 (19.6) 31.1 (20.7) 0.88
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two patients had withdrawn consent and one patient had died.
At 12 months, 14/17 (82%) risedronate patients remained in
the study, 11 of whom were still taking the study medication.
Three patients had withdrawn from the study completely (due to
bone pain) and three patients discontinued the study medication
(one patient citing bone pain and two patients citing muscle
aches/generalised pain) but remained in the study for follow up.
By 24 months, 12/19 (63%) placebo patients remained in the
study, three patients had withdrawn consent and four patients
had died.
By 24 months, 12/17 (71%) risedronate patients remained in
the study, nine of whom were still taking the study drug.
Between 12 and 24 months one further patient withdrew from
the study (citing bone pain) and one patient died.
3.1. Demographic and clinical characteristics
The baseline demographic and clinical characteristics of the
36 patients who were randomised are summarised in Tables 1
and 2. There were no significant differences in demographic or
clinical characteristics between participants randomised to the
risedronate or placebo groups.
3.2. Change in bone mineral density
The percentage changes in BMD from baseline in the
risedronate and placebo groups after 12 and 24 months
treatment are summarised in Table 3. Primary outcome data
were available for 12/17 (71%) of the risedronate group and
12/19 (63%) of the placebo group. Treatment with risedronate
led to a significant increase in the primary outcome (LS BMD),
compared to placebo (mean difference 4.3 (95% CI 0.4, 8.2) %,
p=0.03) over a two-year period. There was a non-significantTable 1
Demographic and clinical details of patients in risedronate and placebo groups.
Risedronate n=17 Placebo n=19 p
Age (years) 30.2 (12.0) 27.8 (8.0) 0.49
Males a 13 (76%) 14 (74%) 1.0
F508 del homozygous a 7 (41%) 14 (74%) 0.09
FEV1 (L) 2.10 (0.74) 2.04 (1.28) 0.86
FEV1% predicted 56.0 (22.2) 53.5 (28.5) 0.77
Height (cm) 170.9 (6.4) 167.7 (8.2) 0.20
Weight (kg) 65.6 (10.1) 59.9 (11.4) 0.12
BMI (kg/m2 ) 22.5 (3.2) 21.2 (3.1) 0.24
Pancreatic sufficient a 2 (12%) 1 (5%) 0.59
Pseudomonas aeruginosa a 13 (76%) 17 (89%) 0.39
Days of intravenous antibiotic
use in the 12 months before
screening visit b
6 (28) 35 (70) 0.11
C reactive protein (mg/L) b
(normal range 0–6.0)
5 (8) 6 (21) 0.41
Patients prescribed oral
glucocorticoids in the
12 months before the
screening visit a
4 (24%) 1 (5%) 0.17
Data are presented as mean (SD) unless otherwise stated.
a Values are given as No. (%).
b Values are given as Median (IQR).improvement in TH BMD in risedronate treated patients
compared to placebo (mean difference 4.0 (95% CI −0.5, 8.6) %,
p=0.08), and in FN BMD (mean difference 2.4 (95% CI −3.5,
8.2) %, p=0.41).
Fig. 2 shows the mean percentage change (95% CI) in LS,
TH and FN BMD from baseline in the risedronate and placebo
groups after 12 and 24 months treatment.3.3. Serum CTX
The median (IQR) serum CTX concentrations in the
risedronate and placebo groups at baseline were: 0.32 (0.64)
ng/ml vs 0.37 (0.55) ng/ml, p=1.00, respectively. The median
(IQR) serum CTX concentrations in the risedronate and placeboTable 3
Percentage change from baseline in absolute bone mineral density in the
risedronate and placebo groups after 12 and 24 months treatment.
Risedronate Placebo Difference R—P
adjusted for baseline
(95% CI)
p
Change from baseline in
lumbar spine BMD
after 12 months
4.3 (7.0)% −1.2
(6.4)%
5.8 (1.2, 10.4)% 0.02
(n=14)
(n=15)
Change from baseline in
lumbar spine BMD
after 24 months
3.1 (5.5)% 0.1
(4.3)%
4.3 (0.4, 8.2)% 0.03
(n=12)
(n=12)
Change from baseline in
total hip BMD after
12 months
2.1 (7.3)% −1.7
(2.9)%
3.6 (−1.1, 8.3)% 0.13
(n=13)
(n=15)
Change from baseline in
total hip BMD after
24 months
2.0 (5.8)% −2.0
(3.6)%
4.0 (−0.5, 8.6)% 0.08
(n=11)
(n=12)
Change from baseline in
femoral neck BMD
after 12 months
2.5 (7.3)% −1.1
(4.7)%
3.5 (−1.7, 8.7)% 0.18
(n=13)
(n=15)
Change from baseline in
femoral neck BMD
after 24 months
1.0 (7.5)% −1.3
(5.4)%
2.4 (−3.5, 8.2)% 0.41
(n=11)
(n=12)
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0.46 (0.75) ng/ml, p=0.02, respectively.
3.4. Fractures
One patient had a vertebral fracture identified at the baseline
visit. There were no new vertebral fractures identified at the end
of the study. There were no new rib or long bone fractures
reported during the study period.A
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Fig. 2.Mean percentage change (95%CI) in bone mineral density from baseline to
12 and 24 months for completers at A) the lumbar spine B) the total hip and C) the
femoral neck.3.5. Adherence
Participants were considered adherent if the residual tablet
count at a study visit suggested that study medication had been
taken correctly N80% of the time. Of the 12 placebo patients
who remained on the study medication throughout the study,
four were adherent at each study visit. Of the nine risedronate
patients who remained on the study medication throughout the
study, five were adherent at each study visit.
3.6. Adverse events
Three hundred and forty six adverse events were recorded
within two years of randomisation. Most events were classed as
respiratory exacerbations (n=230) and there was no difference in
incidence between the two groups. Gastrointestinal symptoms
were also common (n=42) and there was an excess in the
risedronate group (26 vs. 16). These events corresponded to the
same number of patients in each study group (nine in risedronate,
nine in placebo).
Bone pain was recorded 19 times by nine different
risedronate patients in the first year after randomisation, while
there were no episodes of bone pain in the placebo group.
Fourteen of 19 (74%) episodes occurred within the first 56 days
after randomisation. Five events (26%) were classified as severe
and led to the discontinuation of the study medication. Of the
other events, ten were classified as moderate and four as mild.
Only two (11%) events were considered to be unrelated to the
study medication. There were no differences in baseline CRP,
25-hydroxyvitamin D, PTH or CTX levels between the
risedronate patients that experienced bone pain and those that
did not (pN0.5 for all). However, the median (IQR) number of
intravenous antibiotic days in the year prior to randomisation
was 28 (42) for risedronate treated patients that developed bone
pain vs 0 (3) for those that did not (p=0.01).
Overall in the two-year followup, therewas an excess of events
in the risedronate arm,mostly due to bone pain and gastrointestinal
problems. This was significant for the non-serious adverse events
(Relative Risk=1.52, 95%CI 1.18 to 1.96, p=0.0008), but not for
the serious adverse events (Relative Risk=1.17, 95% CI 0.76 to
1.79, p=0.46).
4. Discussion
This is the first trial assessing the efficacy, safety and toler-
ability of risedronate in adults with CF. The results show that
treatment with risedronate led to a significant increase in LSBMD
compared to placebo (mean difference 4.3 (95% CI 0.4, 8.2) %,
p=0.03) over a two-year period. Similar but non-significant
trends were seen at the proximal femur. The significant reduction
in serum CTX in the risedronate treated patients after six months
is consistent with inhibition of osteoclastic bone resorption.
There was no excess of serious adverse events associated
with the use of risedronate. However, seven out of 17 (41%)
patients in the risedronate group discontinued the study drug or
withdrew from the study completely, citing bone pain or muscle
aches / generalised pain as the reason. Flu-like symptoms occur
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first dose of intravenous zoledronic acid [26] and these symptoms
occur due to the release of pro-inflammatory cytokines from
activated T cells [27]. Bone pain was a commonly reported
adverse event in the intravenous pamidronate and zoledronic acid
studies in CF [12,13,16], but not the oral alendronate studies
[14,15]. It remains unclear why bone pain should occur more
commonly with risedronate than alendronate in people with CF.
Potential explanations include differences in the populations
studied, medication specific differences or differences in the
definitions of adverse events. Baseline vitamin D levels were
suboptimal in some risedronate treated patients which could
predispose patients to develop bone pain through bisphosphonate
induced osteomalacia or bisphosphonate induced secondary
hyperparathyroidism, but there were no differences in baseline
vitamin D, PTH or CTX levels between those that developed pain
and those that did not. Furthermore, bone pain was a common
adverse event in the Australian study of intravenous zoledronic
acid, the participants of which were vitamin D replete [13]. While
there was also no difference in baseline CRP between risedronate
treated patients that developed bone pain and those that did not, the
significantly greater requirement for intravenous antibiotic treat-
ment in the year prior to randomisation in those that developed
bone pain suggests that an individual's antibiotic history (a possible
surrogate marker of pulmonary inflammation) may be useful in
predicting the likelihood of bone pain after starting bisphosphonate
therapy.
Consistent with previous reports [12,13,16], bone pain in the
current study involved the vertebrae, ribs and long bones. It
usually started within 24 h of the first dose of risedronate and
lasted for approximately 72 h. Five events were classified as
severe and led to discontinuation of the study medication. There
were no reported episodes of bone pain in the placebo group.
The prescription of paracetamol and ibuprofen prior to and after
taking risedronate appeared to reduce the severity of bone pain /
flu like symptoms in some patients. In a previous study, intra-
venous antibiotics and / or oral glucocorticoids administered
before the first dose of intravenous pamidronate appeared to
reduce the likelihood of bone pain in adults with CF [28], but
Chapman and colleagues found no such effect when oral
glucocorticoids were given for a short time before and after the
first infusion of zoledronic acid [13]. It is now clear that bone
pain occurs after both intravenous and oral bisphosphonates in
patients with CF and it is possible that a course of intravenous
antibiotics administered before starting bisphosphonate therapy
may reduce the likelihood of bone pain through decreasing
pulmonary inflammation.
The magnitude of change in BMD in the current study is
broadly comparable to that observed in the other oral bisphos-
phonate studies in CF. In a 12-month study comparing the effect
of alendronate 70 mg once weekly with placebo, alendronate
patients gained 5.2 (3.7) and 2.1 (3.3)% in the LS and TH BMD,
versus placebo patients who lost 0.08 (3.9) (pb0.001) and 1.3
(2.7)% (pb0.001), respectively [15]. In a 12-month study
comparing the effect of alendronate 10 mg daily with placebo,
alendronate treated patients gained 4.9 (3.0)% and 2.8 (3.2)% in
spine and femur BMD versus placebo patients who lost 1.8(4.0)% (pb0.001) and 0.7 (4.7)% (p=0.003), respectively [14].
However, the magnitude of change in BMD appears greater
following intravenous bisphosphonates in patients with CF,
particularly in the proximal femur where rates of bone loss tend
to be highest in untreated CF patients [3]. In a 24-month trial
comparing the effect of intravenous zoledronic acid with
placebo, the zoledronic acid group gained 6.1 (1.9)% and 4.2
(1.3)% in LS and FN BMD, versus placebo patients who gained
0.44 (0.10)% (p=0.021) and lost 2.5 (1.4)% (p=0.0028),
respectively [13]. This apparent difference between the oral and
intravenous preparations does not reflect the longer duration of
the intravenous zoledronic acid study as the majority of change
in BMD was evident after 12 months treatment [13]. This
observation is further supported by the findings of a six-month
trial investigating the effect of three monthly pamidronate
infusions on BMD in adults with CF. Pamidronate treated
patients showed a significant increase in BMD compared to
controls in the LS (mean difference 5.8%, 95% CI 2.7% to 8.9%)
and total hip (mean difference 3.0%, 95% CI 0.3% to 5.6%)
after only two doses [12]. Due to the poor gastrointestinal
absorption and adherence issues associated with oral bisphos-
phonates in the general population [29], intravenous bisphos-
phonates are likely to be more effective at increasing BMD in
patients with CF.
This study has several limitations. Although the primary
outcome measure was met, the sample size was small. The high
incidence of bone pain made recruitment to the study
increasingly difficult and ultimately reduced its power.
Suboptimal adherence may also have diluted the treatment
effect, but reflects the reality of prescribing a medicine with a
complex administration regimen in an already overburdened
patient population. As with other bisphosphonate studies in CF
[12–15], the current study was not powered to demonstrate a
change in fracture incidence and relies on BMD as a surrogate
marker of bone health. Furthermore, the BMD threshold at
which bisphosphonate treatment should be initiated and the
duration of treatment has not been addressed by this study.
In conclusion, after two years treatment there was a
significant increase in LS BMD with weekly risedronate
compared to placebo. As risedronate is believed to have a
shorter half life in bone than other more potent bisphosphonates,
risedronate may be a preferable option for females who wish to
become pregnant (following cessation of bisphosphonate
therapy) in the future. Strategies to reduce the incidence of
bone pain following bisphosphonate treatment need to be
evaluated in adults with CF.
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